



PLEASE SCAN OR COD

Name : Mrs. SWATHI OLADRI TID : UMR1893441

Age/Gender: 34 Years/FemaleRegistered On: 26-Aug-2024 08:33 AMRef By: SelfReported On: 26-Aug-2024 01:32 PM

Reg.No : BIL4634115 Reference : Arcofemi Health Care Ltd

- Medi Whe

### DEPARTMENT OF ULTRASOUND Ultrasound Whole Abdomen

**LIVER** is normal shape, size (13.9 cms) and has uniform echopattern. No evidence of focal lesion. No intrahepatic biliary ductal dilatation. Hepatic and portal vein radicals are normal.

**GALL BLADDER**: Contracted. No evident calculi.

CBD is of normal calibre.

**PANCREAS**: Head and body are normal.

**SPLEEN** shows normal shape, size (8.6 cms) and echopattern.

**KIDNEYS** move well with respiration and have normal shape, size and echopattern. Cortico- medullary differentiations are well madeout.

No evidence of calculus or hydronephrosis.

Right kidney measures :  $8.8 \times 4.0 \text{ cms}$ , Left kidney measures :  $8.6 \times 4.7 \text{ cms}$ .

**URINARY BLADDER** shows normal shape and wall thickness.

It has clear contents. No evidence of diverticula.

**UTERUS** is anteverted has normal shape and size.

It has uniform myometrial echopattern.

Endometrial echo is of normal thickness: 10 mm.

Uterus measures :  $10.4 \times 5.0 \times 5.5$  cms.

**OVARIES** are normal in size, shape and echotexture. Right ovary: 2.8 x 1.5 cms, Left ovary: 2.8 x 1.6 cms.

No evidence of free fluid in the abdomen and pelvis.





PLEASE SCAN OR CODE

Name : Mrs. SWATHI OLADRI TID : UMR1893441

Age/Gender: 34 Years/FemaleRegistered On: 26-Aug-2024 08:33 AMRef By: SelfReported On: 26-Aug-2024 01:32 PM

Reg.No : BIL4634115 Reference : Arcofemi Health Care Ltd

- Medi Whe

### **IMPRESSION:**

### \* NO SONOGRAPHIC ABNORMALITY DETECTED.

- Suggested clinical correlation and follow up.

\*\*\* End Of Report \*\*\*

**Dr. Apoorva K**Consultant Radiologist





: Mrs . SWATHI OLADRI Name TID : UMR1893441

Age/Gender : 34 Years/Female Registered On : 26-Aug-2024 08:33 AM Ref By : 26-Aug-2024 04:48 PM : Self Reported On Reg.No : BIL4634115

Reference : Arcofemi Health Care Ltd

- Medi Whe

### **DEPARTMENT OF X-RAY** X-Ray Chest PA View

**CLINICAL DETAILS:** Health checkup.

### **FINDINGS:**

Lung fields appear normal.

Cardiac size is within normal limits.

Aorta and pulmonary vasculature is normal.

Bilateral domes of diaphragm and costophrenic angles are normal.

Visualised bones and soft tissues appear normal.

### **IMPRESSION:**

### \* NORMAL STUDY.

- Suggested clinical correlation and follow up.

\*\*\* End Of Report \*\*\*

Dr.Kiranchander Reg.No - 58122 Consultant Radiologist







:UMR1893441/ 28141081

Name : MRS.SWATHI OLADRI

Age / Gender : 34 Years / Female

Ref.By : SELF

Reg.No : BIL4634115

Registered on: 26-Aug-2024 / 08:33 AM
Collected on: 26-Aug-2024 / 08:33 AM
Reported on: 26-Aug-2024 / 10:30 AM

TEST REPORT Reference : Arcofemi Health Care Ltd -

TID/SID

### **DEPARTMENT OF CLINICAL PATHOLOGY**

### Complete Urine Examination (CUE), Urine

Investigation	Result	Biological Reference Intervals
Physical Examination		
Colour	LightYellow	Straw to Yellow
Method:Physical		
Appearance	Clear	Clear
Method:Physical		
Chemical Examination		
Reaction and pH Method:Indicator	Acidic (5.0)	4.6-8.0
Specific gravity	1.002	1.000-1.035
Method:Refractometry		
Protein	Negative	Negative
Method:Protein Error of pH indicators		
Glucose	Negative	Negative
Method:Glucose oxidase/Peroxidase		
Blood	Negative	Negative
Method:Peroxidase	Namathia	Namethy
Ketones	Negative	Negative
Method:Sodium Nitroprusside	Negative	Negative
Bilirubin Method:Diazonium salt	Negative	rvegative
	Negative	Negative
Leucocytes Method:Esterase reaction	regative	Nogalivo
Nitrites	Negative	Negative
Method:Modified Griess reaction	9	
Urobilinogen	Negative	Up to 1.0 mg/dl
Method:Diazonium salt	•	(Negative)
Microscopic Examination		
Pus cells (leukocytes)	2-3	2 - 3 /hpf
Method:Flow Digital Imaging/Microscopy		
Epithelial cells	2-3	2 - 5 /hpf
Method:Flow Digital Imaging/Microscopy		
RBC (erythrocytes)	Absent	Absent
Method:Flow Digital Imaging/Microscopy		
Casts	Absent	Occasional hyaline casts may be seen
Method:Flow Digital Imaging/Microscopy		







TO VERIFY THE REPORT ONLINE

: MRS.SWATHI OLADRI Name : 34 Years / Female Age / Gender

Ref.By : SELF

Req.No : BIL4634115 TID/SID :UMR1893441/ 28141081

Registered on: 26-Aug-2024 / 08:33 AM

Collected on : 26-Aug-2024 / 08:33 AM

Reported on : 26-Aug-2024 / 10:30 AM

Reference : Arcofemi Health Care Ltd -**TEST REPORT** 

Absent Phosphate, oxalate, or urate crystals may Crystals be seen

Method:Flow Digital Imaging/Microscopy

Nil Nil Others

Method:Flow Digital Imaging/Microscopy

### Method: Semi Quantitative test ,For CUE

Reference: Godkar Clinical Diagnosis and Management by Laboratory Methods, First South Asia edition. Product kit literature.

### Interpretation:

The complete urinalysis provides a number of measurements which look for abnormalities in the urine. Abnormal results from this test can be indicative of a number of conditions including kidney disease, urinary tract infecation or elevated levels of substances which the body is trying to remove through the urine. A urinalysis test can help identify potential health problems even when a person is asymptomatic. All the abnormal results are to be correlated clinically.

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

Dr Vikas Reddy **Consultant Pathologist** 







Name : MRS.SWATHI OLADRI

Age / Gender : 34 Years / Female

Ref.By : SELF

Reg.No : BIL4634115

TID/SID : UMR1893441/ 28143068 Registered on : 26-Aug-2024 / 08:33 AM

Collected on : 26-Aug-2024 / 12:40 PM Reported on : 27-Aug-2024 / 17:03 PM

Reference : Arcofemi Health Care Ltd -

### **DEPARTMENT OF CYTOPATHOLOGY**

**TEST REPORT** 

### Pap Smear, Conventional

Cytology No C-9143/24

Clinical Details For screening.

Specimen Type Conventional smear (Pap smear)

Specimen Adequacy Satisfactory for evaluation without evidence of

endocervical/transformation zone component

Microscopic Observations: Smear contains superficial, intermediate and parabasal cells. Dense

inflammation noted.

Organisms Not present

Non-neoplastic findings Reactive cellular changes associated with inflammation

Interpretation Negative for intraepithelial lesion or malignancy.

Inflammatory smear

Note Advice repeat after control of inflammation

Method: Pap staining & microscopy

Reported as per the 2014 Bethesda System

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

Dr Shruti Reddy Consultant Pathologist Reg No.TSMC/FMR/22656







Name : MRS.SWATHI OLADRI

Age / Gender : 34 Years / Female

Ref.By : SELF

Reg.No : BIL4634115

TID/SID : UMR1893441/ 28141082 Registered on : 26-Aug-2024 / 08:33 AM

Collected on : 26-Aug-2024 / 08:33 AM

Reported on : 26-Aug-2024 / 12:47 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

### **DEPARTMENT OF HEMATOPATHOLOGY**

### **Blood Grouping ABO And Rh Typing, EDTA Whole Blood**

Parameter Results

Blood Grouping (ABO) A

Rh Typing (D) Positive

Method:Hemagglutination Tube Method by Forward & Reverse Grouping

Method: Hemagglutination Tube Method by Forward & Reverse Grouping

Reference: Tulip kit literature

**Interpretation:** The ABO grouping and Rh typing test determines blood type grouping (A,B, AB, O) and the Rh factor (positive or negative). A person's blood type is based on the presence or absence of certain antigens on the surface of their red blood cells and certain antibodies in the plasma. ABO antigens are poorly expresses at birth, increase gradually in strength and become fully expressed around 1 year of age.

In case of Rh(D) - Du(weak positive) or Weak D positive, the individual must be considered as Rh positive as donor and Rh negative as recipient.

Note: Records of previous blood grouping/Rh typing not available. Please verify before transfusion.

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

Dr Shruti Reddy Consultant Pathologist Reg No.TSMC/FMR/22656





:UMR1893441/ 28141082

Name

: MRS.SWATHI OLADRI

: 34 Years / Female Age / Gender

Ref.By : SELF

Req.No : BIL4634115 Reported on : 26-Aug-2024 / 12:28 PM

**TEST REPORT** 

Reference : Arcofemi Health Care Ltd -

Registered on: 26-Aug-2024 / 08:33 AM

Collected on : 26-Aug-2024 / 08:33 AM

### **DEPARTMENT OF HEMATOPATHOLOGY** Erythrocyte Sedimentation Rate (ESR), Whole Blood Biological Reference Intervals Observed Value 15 <=12 mm/hour

TID/SID

Method:Westergren/Vesmatic

Investigation

ESR 1st Hour

### Complete Blood Count (CBC), EDTA Whole Blood

Investigation	Observed Value	Biological Reference Intervals
Hemoglobin	12.3	12.0-15.0 g/dL
Method:Cyanide Free Lyse Hemoglobin		
PCV/HCT	36.7	36.0-46.0 vol%
Method:Calculated		
Total RBC Count	4.84	3.80-4.80 mill /cu.mm
Method:Electrical Impedance		
MCV	75.9	83.0-101.0 fL
Method:Calculated		
MCH	25.4	27.0-32.0 pg
Method:Calculated	00.4	04.5.04.5///
MCHC	33.4	31.5-34.5 g/dL
Method:Calculated	17.0	11.6-14.0 %
RDW (CV) Method:Calculated	17.0	11.0-14.0 76
MPV	8.1	7.0-10.0 fL
Method:Calculated	0.1	7.0 10.0 12
Total WBC Count	5380	4000-10000 cells/cumm
Method:Electrical Impedance		
Platelet Count	2.86	1.50-4.10 lakhs/cumm
Method:Electrical Impedance		
Differential count		
Neutrophils	50.3	40.0-80.0 %
Method:Microscopy		
Lymphocytes	38.3	20.0-40.0 %
Method:Microscopy		
Eosinophils	1.4	1.0-6.0 %
Monocytes	9.1	2.0-10.0 %
Basophils	0.9	< 1.0-2.0 %
Method:Microscopy		





Name : MRS.SWATHI OLADRI

Age / Gender : 34 Years / Female

Ref.By : SELF

Reg.No : BIL4634115

TID/SID : UMR1893441/ 28141082

Registered on: 26-Aug-2024 / 08:33 AM

Collected on : 26-Aug-2024 / 08:33 AM Reported on : 26-Aug-2024 / 12:28 PM

Reference : Arcofemi Health Care Ltd -

Absolute Neutrophil Count 2706 2000-7000 cells/cumm

**TEST REPORT** 

Method:Calculated

Absolute Lymphocyte Count (ALC) 2061 1000-3000 cells/cumm

Absolute Eosinophil Count (AEC) 75 20-500 cells/cumm

Absolute Monocyte Count 490 200-1000 cells/cumm

Method:Calculated

Absolute Basophil Count 48 20-100 cells/cumm

Method:Calculated

Neutrophil - Lymphocyte Ratio(NLR) 1.31 0.78-3.53

Method:Calculated

Method: Automated Hematology Cell Counter, Microscopy

**Reference:** Dacie and Lewis Practical Hematology, 12th Edition. Wallach's interpretation of diagnostic tests, Soth Asian Edition.

**Interpretation:** A Complete Blood Picture (CBP) is a screening test which can aid in the diagnosis of a variety of conditions and diseases such as anemia, leukemia, bleeding disorders and infections. This test is also useful in monitoring a person's reaction to treatment when a condition which affects blood cells has been diagnosed. All the abnormal results are to be correlated clinically.

**Note:** These results are generated by a fully automated hematology analyzer and the differential count is computed from a total of several thousands of cells. Therefore the differential count appears in decimalised numbers and may not add upto exactly 100. It may fall between 99 and 101.

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

Dr Shruti Reddy Consultant Pathologist Reg No.TSMC/FMR/22656







Name : MRS.SWATHI OLADRI

: SELF

Age / Gender : 34 Years / Female

Reg.No : BIL4634115

Ref.By

TEGT DEDGE

TID/SID : UMR1893441/ 28141084F Registered on : 26-Aug-2024 / 08:33 AM Collected on : 26-Aug-2024 / 08:33 AM Reported on : 26-Aug-2024 / 11:53 AM

TEST REPORT Reference : Arcofemi Health Care Ltd -

### Blood Urea Nitrogen (BUN), Serum Investigation Observed Value Biological Reference Interval Blood Urea Nitrogen. 13 6-20 mg/dL Method:Calculated Urea. 26.8 12.8-42.8 mg/dL

**Interpretation:** Urea is a waste product formed in the liver when protein is metabolized. Urea is released by the liver into the blood and is carried to the kidneys, where it is filtered out of the blood and released into the urine. Since this is a continuous process, there is usually a small but stable amount of urea nitrogen in the blood. However, when the kidneys cannot filter wastes out of the blood due to disease or damage, then the level of urea in the blood will rise. The blood urea nitrogen (BUN) evaluates kidney function in a wide range of circumstances, to diagnose kidney disease, and to monitor people with acute or chronic kidney dysfunction or failure. It also may be used to evaluate a person's general health status as well.

Reference: Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics

### Creatinine, Serum

Investigation	Observed Value	Biological Reference Interval
Creatinine.	0.7	0.50-0.90 mg/dL
Method:Alkaline Picrate		

### Interpretation:

Method:Urease/UV

Creatinine is a nitrogenous waste product produced by muscles from creatine. Creatinine is majorly filtered from the blood by the kidneys and released into the urine, so serum creatinine levels are usually a good indicator of kidney function. Serum creatinine is more specific and more sensitive indicator of renal function as compared to BUN because it is produced from muscle at a constant rate and its level in blood is not affected by protein catabolism or other exogenous products. It is also not reabsorbed and very little is secreted by tubules making it a reliable marker. Serum creatinine levels are increased in pre renal, renal and post renal azotemia, active acromegaly and gigantism. Decreased serum creatinine levels are seen in pregnancy and increasing age.

### Glucose Fasting (FBS), Sodium Fluoride Plasma

	<del>-</del> • • •	
Investigation	Observed Value	Biological Reference Interval
Glucose Fasting Method:Hexokinase	94	Normal: <100 mg/dL Impaired FG: 100-125 mg/dL Diabetes mellitus: >/=126 mg/dL

**Interpretation:** It measures the Glucose levels in the blood with a prior fasting of 9-12 hours. The test helps screen a symptomatic/ asymptomatic person who is at risk for Diabetes. It is also used for regular monitoring of glucose levels in people with Diabetes.

Reference: American Diabetes Association. Standards of Medical Care in Diabetes-2022





TO VERIFY THE REPORT ONLINE

: UMR1893441/ 28141083

: MRS.SWATHI OLADRI Name

: 34 Years / Female Age / Gender

Ref.By : SELF

: BIL4634115 Reg.No

Collected on : 26-Aug-2024 / 08:33 AM Reported on : 26-Aug-2024 / 11:55 AM

Registered on: 26-Aug-2024 / 08:33 AM

Reference : Arcofemi Health Care Ltd -**TEST REPORT** 

TID/SID

### Glucose Post Prandial (PPBS), Sodium Fluoride Plasma

Investigation	Observed Value	Biological Reference Interval
Glucose Post Prandial Method:Hexokinase	95	Normal : <140 mg/dL Impaired PG: 140-199 mg/dL Diabetes mellitus: >/=200 mg/dL

Interpretation: This test measures the blood sugar levels 2 hours after a normal meal. Abnormally high blood sugars 2 hours after a meal reflect that the body is not producing sufficient insulin which is indicative of Diabetes.

Reference: American Diabetes Association. Standards of Medical Care in Diabetes-2022

### Glycosylated Hemoglobin (HbA1C), EDTA Whole Blood

Investigation	Observed Value	Biological Reference Interval
Glycosylated Hemoglobin (HbA1c) Method:High-Performance Liquid Chromatography	5.3	Non-diabetic: <= 5.6 % Pre-diabetic: 5.7 - 6.4 % Diabetic: >= 6.5 %
Estimated Average Glucose (eAG)	105	mg/dL

### Interpretation:

It is an index of long-term blood glucose concentrations and a measure of the risk for developing microvascular complications in patients with diabetes. Absolute risks of retinopathy and nephropathy are directly proportional to the mean HbA1c concentration. In persons without diabetes, HbA1c is directly related to risk of cardiovascular disease.

- 1) Low glycated haemoglobin (below 4%) in a non-diabetic individual are often associated with systemic inflammatory diseases, chronic anaemia (especially severe iron deficiency & haemolytic), chronic renal failure and liver diseases. Clinical correlation suggested.
- 2) Interference of Hemoglobinopathies in HbA1c estimation:
- A. For HbF > 25%, an alternate platform (Fructosamine) is recommended for testing of HbA1c.
- B. Homozygous hemoglobinopathy is detected, fructosamine is recommended for monitoring diabetic status
- C. Heterozygous state detected (D10 is corrected for HbS and HbC trait).
- 3) In known diabetic patients, HbA1c can be considered as a tool for monitoring the glycemic control. Excellent Control - 6 to 7 %,

Fair to Good Control - 7 to 8 %,

Unsatisfactory Control - 8 to 10 %

and Poor Control - More than 10 %.

Reference: American Diabetes Association. Standards of Medical Care in Diabetes-2022.

### **Bun/Creatinine Batio Serum**

	Duil/Orealinine ria	illo, Serum	
Investigation	Observed Valu	ne -	
BUN/Creatinine Ratio Method:Calculated	17.0	10-20	





:UMR1893441/ 28141083

Registered on: 26-Aug-2024 / 08:33 AM Collected on: 26-Aug-2024 / 08:33 AM

Name : MRS.SWATHI OLADRI

Age / Gender : 34 Years / Female

Ref.By : SELF

Req.No : BIL4634115 Reported on : 26-Aug-2024 / 11:55 AM

TEST REPORT Reference : Arcofemi Health Care Ltd -

TID/SID

### Interpretation:

The BUN/Creatinine ratio blood test is used to diagnose acute or chronic renal disease. BUN (blood urea nitrogen) and creatinine are both filtered in the kidneys and excreted in urine. The two together are used to measure overall kidney function

- 1. Increased ratio (>20) with normal creatinine occurs in the following conditions:
- a) Increased BUN (prerenal azotemia), heart failure, salt depletion, dehydration
- b) Catabolic states with tissue breakdown
- c) GI hemorrhage
- d) Impaired renal function plus excess protein intake, production, or tissue breakdown
- 2. Increased ratio (>20) with elevated creatinine occurs in the following conditions:
- a) Obstruction of urinary tract
- b) Prerenal azotemia with renal disease
- 3. Decreased ratio (<10) with decreased BUN occurs in the following conditions:
- a) Acute tubular necrosis
- b) Decreased urea synthesis as in severe liver disease or starvation
- c) Repeated dialysis
- d) SIADH
- e) Pregnancy
- 4. Decreased ratio (<10) with increased creatinine occurs in the following conditions:
- a) Phenacemide therapy (accelerates conversion of creatine to creatinine)
- b) Rhabdomyolysis (releases muscle creatinine)
- c) Muscular patients who develop renal failure
- \* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---







:UMR1893441/ 28141083

Name : MRS.SWATHI OLADRI

Age / Gender : 34 Years / Female

Ref.By : SELF

Reg.No : BIL4634115

Collected on : 26-Aug-2024 / 08:33 AM

Reported on : 26-Aug-2024 / 11:55 AM

Registered on: 26-Aug-2024 / 08:33 AM

TEST REPORT Reference : Arcofemi Health Care Ltd -

TID/SID

### **DEPARTMENT OF CLINICAL CHEMISTRY I**

### Lipid Profile, Serum

	Lipia i follic, octui	11
Investigation	Observed Value	Biological Reference Interval
Total Cholesterol Method:Cholesterol Oxidase	169	Desirable: <200 mg/dL Borderline: 200-239 mg/dL High: >/=240 mg/dL
HDL Cholesterol Method:Direct Measurement	53	Low: <40 mg/dL High: >/=60 mg/dL
VLDL Cholesterol Method:Calculated	10.80	6.0-38.0 mg/dL
LDL Cholesterol Method:Calculated	105.2	Optimum: <100 mg/dL Near/above optimum: 100-129 mg/dL Borderline: 130-159 mg/dL High: 160-189 mg/dL Very high: >/=190 mg/dL
Triglycerides Method:Glycerol LPL/GK	54	Normal:<150 mg/dL Borderline: 150-199 mg/dL High: 200-499 mg/dL Very high: >/=500 mg/dL
Chol/HDL Ratio Method:Calculated	3.19	Low Risk: 3.3-4.4 Average Risk: 4.5-7.1 Moderate Risk: 7.2-11.0
LDL Cholesterol/HDL Ratio Method:Calculated	1.98	Desirable: 0.5-3.0 Borderline Risk: 3.0-6.0 High Risk: >6.0

Interpretation: Lipids are fats and fat-like substances which are important constituents of cells and are rich sources of energy. A lipid profile typically includes total cholesterol, high density lipoproteins (HDL), low density lipoprotein (LDL), chylomicrons, triglycerides, very low density lipoproteins (VLDL), Cholesterol/HDL ratio .The lipid profile is used to assess the risk of developing a heart disease and to monitor its treatment. The results of the lipid profile are evaluated along with other known risk factors associated with heart disease to plan and monitor treatment. Treatment options require clinical correlation.

**Reference:** Third Report of the National Cholesterol Education program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 2001.

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

Dr Afreen Anwar Consultant Biochemist







:UMR1893441/ 28141083

Name : MRS.SWATHI OLADRI

Age / Gender : 34 Years / Female

Ref.By : SELF

Reg.No : BIL4634115

Registered on: 26-Aug-2024 / 08:33 AM Collected on: 26-Aug-2024 / 08:33 AM Reported on: 26-Aug-2024 / 11:55 AM

TEST REPORT Reference : Arcofemi Health Care Ltd -

TID/SID

### **DEPARTMENT OF CLINICAL CHEMISTRY I**

### Liver Function Test (LFT), Serum

Investigation	Observed Value	Biological Reference Interval
Total Bilirubin. Method:Diazo method	0.42	<1.2 mg/dL
Direct Bilirubin. Method:Diazo method	0.24	<0.30 mg/dL
Indirect Bilirubin. Method:Calculated	0.18	<0.9 mg/dL
Alanine Aminotransferase ,(ALT/SGPT) Method:UV wtihout P5P	14	<34 U/L
Aspartate Aminotransferase,(AST/SGOT) Method:UV wtihout P5P	21	<31 U/L
ALP (Alkaline Phosphatase).  Method:PNPP-AMP Buffer	63	35-104 U/L
Gamma GT.  Method:Gamma-Glutamyl - 3 - Carbossi - 4 - Nitroanilide (GCNA)	14	6-42 U/L
Total Protein. Method:Biuret	7.1	6.6-8.7 g/dL
Albumin.  Method:Bromocresol Green (BCG)	4.4	3.5-5.2 g/dL
Globulin. Method:Calculated	2.70	1.8-3.8 g/dL
A/GRatio.  Method:Calculated	1.60	0.8-2.0

**Interpretation:** Liver functions tests help to identify liver disease, its severity, and its type. Generally these tests are performed in combination, are abnormal in liver disease, and the pattern of abnormality is indicative of the nature of liver disease. An isolated abnormality of a single liver function test usually means a non-hepatic cause. If several liver function tests are simultaneously abnormal, then hepatic etiology is likely.

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---







TO VERIFY THE REPORT ONLINE

: MRS.SWATHI OLADRI Name

Age / Gender : 34 Years / Female

Reg.No

: BIL4634115

: SELF

TID/SID :UMR1893441/ 28141083 Registered on: 26-Aug-2024 / 08:33 AM

Collected on : 26-Aug-2024 / 08:33 AM Reported on : 26-Aug-2024 / 11:55 AM

Reference : Arcofemi Health Care Ltd -

### **DEPARTMENT OF CLINICAL CHEMISTRY I**

**TEST REPORT** 

### Thyroid Profile (T3,T4,TSH), Serum

Investigation	Observed Value	Biological Reference Interval
Triiodothyronine Total (T3) Method:ECLIA	1.28	0.80-2.00 ng/mL Pregnancy: 1st Trimester: 0.81 - 1.90 ng/mL 2nd & 3rd Trimester: 1.00 - 2.60 ng/mL
Thyroxine Total (T4) Method:ECLIA	9.4	5.1-14.1 μg/dL
Thyroid Stimulating Hormone (TSH) Method:ECLIA	1.46	0.27-4.20 μIU/mL Pregnancy: 1st Trimester: 0.1 - 2.5 μIU/mL 2nd Trimester: 0.2 - 3.0 μIU/mL 3rd Trimester: 0.3 - 3.0 μIU/mL

### Interpretation:

A thyroid profile is used to evaluate thyroid function and/or help diagnose hypothyroidism and hyperthyroidism due to various thyroid disorders. T4 and T3 are hormones produced by the thyroid gland. They help control the rate at which the body uses energy, and are regulated by a feedback system. TSH from the pituitary gland stimulates the production and release of T4 (primarily) and T3 by the thyroid. Most of the T4 and T3 circulate in the blood bound to protein. A small percentage is free (not bound) and is the biologically active form of the hormones. Reference: Tietz textbook of Clinial Chemistry and Molecular Diagnostics, Nader Rifia, Andrea Ritas Horvath, Carl T. Wittwer.

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

Dr Afreen Anwar **Consultant Biochemist** 







:UMR1893441/ 28141083

Name : MRS.SWATHI OLADRI

Age / Gender : 34 Years / Female

Ref.By : SELF

Reg.No : BIL4634115

Registered on: 26-Aug-2024 / 08:33 AM
Collected on: 26-Aug-2024 / 08:33 AM
Reported on: 26-Aug-2024 / 11:55 AM

TEST REPORT Reference : Arcofemi Health Care Ltd -

TID/SID

	DEPARTMENT OF CLINICAL C	HEMISTRY I
	Uric Acid, Serum	
Investigation	Observed Value	Biological Reference Interval
Uric Acid. Method:Uricase	4.5	2.4-5.7 mg/dL

### Interpretation

It is the major product of purine catabolism. Hyperuricemia can result due to increased formation or decreased excretion of uric acid which can be due to several causes like metabolic disorders, psoriasis, tissue hypoxia, preeclampsia, alcohol, lead poisoning, acute or chronic kidney disease, etc. Hypouricemia may be seen in severe hepato cellular disease and defective renal tubular reabsorption of uric acid.

\* Sample processed at National Reference Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

Dr Afreen Anwar Consultant Biochemist



### TENET MEDCORP PVT LTD

Summary

GACHIBOWLI, HYDERABAD.

4634115/SWATHI OLADRI 34 Yrs/Female 56 Kg/157 Cms
Date: 26-Aug-2024 12:35:51 PM
Ref. By : ARCOFEMI HEALTH CARE

Objective: Medication: Nil

Protocol: BRUCE History: Nil

Stage	StageTime PhaseTime		speed b	Grade	METS	##.	8.P.	.70	PVC (	Comments		s	2 3R	
Supine				(2)	1.0	84	/	0 8	•			Are grant all properties - 1	Myrando	
Standing					1.0	91	/	0				III malhadi		
ExStart					1.0	86 -	/	0					"	
Stage 1	3:01	3:02	2.7	0.0	4.6	101 -	·/	0						
Stage 2	3:01	6:02	4.0	12.0	7.0	117 T	120/80	140				avR haddadhodhodh	المماليك من الممالية	
Stage 3	3:01	9:02	5.5	14.0	10.2	150 1	140/80	210	4			and Mark		
PeakEx	0:19	9:20	6.8	16.0	10.6	164 1	140/80	229	ı			avL/\////	Wyling or wall	
Recovery	1:00		0.0	0.0	4.3	141 1	150/80	211	1			ave mythet	Milway Late	
Recovery	3:00		0.0	0.0	1.0	108 1	130/80	7	•					
Findings : Exerc	Exercise Time	: 9:19 minutes						140				More and freezently and the	My Monday M	
Max Max	Max HR attained : 16 Max BP : 150/80(mmHg)	: 160 bpn (mmHg)	ites					į				V1 — VIMBAA	V1 - Alphania Alamana Maria	
Work No si	(Load attaine		9:19 minutes : 160 bpm 86% of Max Predictable HR 186	Max Pred	ictable H			140			PreEx	V1 — Children	Myllow W.	
No Ar	ngina / Arrny	WorkLoad attained: 10.6 (Good Effort Tolerance )  No significant ST segment changes noted during exercise or recovery.	ates 1 86% of d Effort To	Max Pred blerance during ex	ictable H	R 186	*	140			- PreEx	V1 — AMMANIAM MANAMAN V2 — AMMANIAM MANAMAN V4 — AMMANIAM MANAMAN	Myhamay Mr.	
Final		WorkLoad attained: 10.6 (Goo No significant ST segment chan No Angina / Arrhythmia / SOB	ites 1 86% of d Effort To	Max Pred Dilerance	ictable H	R 186	*	140			- PreEx	V1 — Alphandaghan Lin	Mylaman Maria	
REPO	. Impression:*	WorkLoad attained: 10.6 (Good Effort Tolerance) No significant ST segment changes noted during exercise or recovery. No Angina / Arrhythmia / SOB  Final Impression:*** TEST IS NEGATIVE FOR EXERCISE INDUCIBLE SICHEMIA***	ites 1 86% of d Effort To ges noted	Max Pred Merance during ex	ictable H ercise or	R 186	EMIA *	1			- PreEx 3	V1 —	All the water of the second of	
	Final Impression:*** REPORTED BY OR R	d: 10.6 (Good segment change thmia / SOB	minutes bpm 86% of Good Effort To Changes noted OB SMEGATIVE FOR	Max Pred Merance during ex	ercise or	R 186 BLE SICH	EMIN X.				PreEx PeakEx	V1 — MANAMANA V2 — MANAMANA V6 — MANAMANANA V6 — MANAMANANA V6 — MANAMANANA V6 — MANAMANANANA V6 — MANAMANANANANANANANANANANANANANANANANAN	My Control March M	18 21 Min.

## TENET MEDCORP PVT LTD GACHIBOWLI, HYDERABAD.

56 Kg/157 Cms Date: 26-Aug-2024 12:35:51 PM 34 Yrs/Female 4634115/SWATHI OLADRI


HR: 84 bpm METS: 1.0 BP: ---/---Stage Report Time: 26-Aug-2024 12:38:15 PM MPHR:45% of 186 Speed: 0.0 kmph Grade: 0.0%

BRUCE (0.05-100)Hz

Linked Medians Report

Ex Time 01:04 BLC :On Notch :On

SUPINE 10.0 mm/mV 25 mm/Sec.



### GACHIBOWLI, HYDERABAD. TENET MEDCORP PVT LTD

4634115/SWATH! OLADR! 34 Yrs/Female 56 Kg/157 Cms

Date: 26-Aug-2024 12:35:51 PM


HR: 91 bpm MPHR:48% of 186
METS: 1.0 Speed: 0.0 kmph
BP: ---/--- Grade: 0.0%
Stage Report Time: 26-Aug-2024 12:38:24 PM

BRUCE (0.05-100)Hz

**Linked Medians Report** 

Ex Time 01:13 BLC :On Notch :On

STANDING 10.0 mm/mV 25 mm/Sec.



### TENET MEDCORP PVT LTD GACHIBOWLI, HYDERABAD.


4634115/SWATHI OLADRI 34 Yrs/Female 56 Kg/157 Cms Date: 26-Aug-2024 12:35:51 PM


BRUCE (0.05-100)Hz

**Linked Medians Report** 

Ex Time 00:00 BLC :On Notch :On

ExStart 10.0 mm/mV 25 mm/Sec.





## TENET MEDCORP PVT LTD GACHIBOWLI, HYDERABAD.

4634115/SWATHI OLADRI 34 Yrs/Female

56 Kg/157 Cms Date: 26-Aug-2024 12:35:51 PM

 HR: 101 bpm
 MPHR:54% of 186

 METS: 4.6
 Speed: 2.7 kmph

 BP: ---/-- Grade: 10.0%


 Stage Report Time: 26-Aug-2024 12:42:16 PM

BRUCE (0.05-100)Hz

Linked Medians Report

Ex Time 03:00 BLC :On Notch :On

Stage 1 ( 03:00 ) 10.0 mm/mV 25 mm/Sec.



## TENET MEDCORP PYT LTD GACHIBOWLI, HYDERABAD.

4634115/SWATHI OLADRI 34 Yrs/Female

56 Kg/157 Cms Date: 26-Aug-2024 12:35:51 PM

 HR: 117 bpm
 MPHR:62% of 186

 METS: 7.0
 Speed: 4.0 kmph

 BP: 120/80
 Grade: 12.0%


 Stage Report Time: 26-Aug-2024 12:45:17 PM

BRUCE (0.05-100)Hz

Linked Medians Report

Ex Time 06:00 BLC :On Notch :On

Stage 2 ( 03:00 ) 10.0 mm/mV 25 mm/Sec.



### GACHIBOWLI, HYDERABAD. TENET MEDCORP PVT LTD

4634115/SWATHI OLADRI

34 Yrs/Female 56 Kg/157 Cms Date: 26-Aug-2024 12:35:51 PM

 HR: 150 bpm
 MPHR:80% of 186

 METS: 10.2
 Speed: 5.5 kmph

 BP: 140/80
 Grade: 14.0%


 Stage Report Time: 26-Aug-2024 12:48:17 PM

BRUCE (0.05-100)Hz

Linked Medians Report

Ex Time 09:00 BLC :On Notch :On

Stage 3 ( 03:00 ) 10.0 mm/mV 25 mm/Sec.



## TENET MEDCORP PYT LTD GACHIBOWLI, HYDERABAD.

4634115/SWATHI OLADRI
463415/SWATHI OLADRI
34 Yrs/Female
56 Kg/157 Cms
Date: 26-Aug-2024 12:35:51 PM


HR: 164 bpm MPHR:88% of 186
METS: 10.6 Speed: 6.8 kmph
BP: 140/80 Grade: 16.0%
Stage Report Time: 26-Aug-2024 12:48:36 PM

Linked Medians Report

BRUCE
(0.05-100)Hz

Ex Time 09:18 BLC :On Notch :On

**PeakEx** 10.0 mm/mV 25 mm/Sec.



### GACHIBOWLI, HYDERABAD. TENET MEDCORP PVT LTD

4634115/SWATHI OLADRI 34 Yrs/Female 56 Kg/157 Cms Date: 26-Aug-2024 12:35:51 PM

# HR: 108 bpm MPHR:58% of 186 METS: 1.0 Speed: 0.0 kmph BP: 130/80 Grade: 0.0% Stage Report Time: 26-Aug-2024 12:51:35 PM **Linked Medians Report**

BRUCE (0.05-100)Hz

Ex Time 09:18 BLC :On Notch :On

Recovery: (02:59)
10.0 mm/mV
25 mm/Sec.

